Turna Ray
Journalist: Personalized medicine, genomics, cancer @GenomeWeb https://t.co/MJTiedX6Di Managing editor: Precision Medicine Online https://t.co/ZhPdXijId5
Articles
-
2 weeks ago |
precisionmedicineonline.com | Turna Ray
NEW YORK – Novartis executives assured investors on Tuesday that if the Trump Administration moves ahead with tariffs on pharmaceuticals, this would not materially impact its business in the near term since it is actively working to expand drug manufacturing in the US. During a call to discuss first quarter financials, Novartis CEO Vas Narasimhan said that the near-term impact of potential tariffs is "manageable" and baked into the firm's guidance for the year.
-
2 weeks ago |
precisionmedicineonline.com | Turna Ray
NEW YORK – GlaxoSmithKline's checkpoint inhibitor Jemperli (dostarlimab) spared 80 percent of patients with earlier-stage solid tumors characterized by mismatch repair deficiency (dMMR) from needing surgery, a study has shown.
-
3 weeks ago |
precisionmedicineonline.com | Turna Ray
NEW YORK – The elimination of the Public Health Genomics Branch (PHGB) at the US Centers for Disease Control and Prevention is yet another blow to the genomics and precision medicine sector. As part of the March 27 reduction in force (RIF), the US Department of Health and Human Services has eliminated 2,400 jobs at the CDC, including those within the Division of Blood Disorders and Public Health Genomics, which housed the PHGB.
-
1 month ago |
360dx.com | Turna Ray
NEW YORK – Reviewers at the US Food and Drug Administration working under the uncertainty and pressure of constantly looming layoffs are concerned about the agency's ability to ensure the safety and efficacy of diagnostics. Since January, President Donald Trump's administration and Elon Musk's Department of Government Efficiency have moved to downsize the federal workforce, including at the FDA.
-
1 month ago |
precisionmedicineonline.com | Turna Ray
NEW YORK – Leading cancer centers and healthcare systems in the US are continuing to improve patients' access to molecular testing for personalizing treatment, assessing cancer risk, and predicting adverse events, Precision Medicine Online's annual survey has found.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 1K
- Tweets
- 3K
- DMs Open
- Yes
RT @MyGeneCounsel: @GenomeWeb @TurnaRay and mGC collaborate on a case series titled "Genetic Testing Challenges." Check out all prior artic…
RT @MyGeneCounsel: T minus one month until the Precision Oncology & Diagnostics Conference held by @GenomeWeb. Register to hear from mGC CE…
RT @eumenes_kardia: A rare occasion: an international conference on Salomon Maimon in Germany. We will celebrate work on the new Maimon com…